Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 78 for:    vismodegib

Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01700049
Recruitment Status : Completed
First Posted : October 4, 2012
Results First Posted : May 23, 2019
Last Update Posted : May 23, 2019
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Scott W. Fosko, Mayo Clinic

Brief Summary:
The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC). The term 'histologic subtype' refers to how the cells and tumor tissue looks under the microscope. Three different 'histologic subtypes' of basal cell skin cancer (infiltrative/morpheaform, nodular and superficial) will be examined in this study.

Condition or disease Intervention/treatment Phase
Basal Cell Carcinoma Drug: vismodegib (150 mg PO daily) Phase 2

Detailed Description:

The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC). The term 'histologic subtype' refers to how the cells and tumor tissue looks under the microscope. Three different 'histologic subtypes' of basal cell skin cancer (infiltrative/morpheaform, nodular and superficial) will be examined in this study. Each subtype has a characteristic look under the microscope, which is related to how the tumor will behave and grow.

ERIVEDGE (oral vismodegib capsule) has been approved for use in the United States for treatment of metastatic BCC tumors (mBCC), tumors that have spread further into the skin, bones or other tissues, or spread to other parts of the body and locally advanced basal cell skin cancer (laBCC), cancers that have come back after surgery or that the healthcare provider thinks cannot be treated with surgery or radiation. It works by blocking the signal, called Hedgehog, which basal cell skin cancer cells need to grow. It has been given to about 800 people during clinical trials.

Data from previous studies is mostly based on a subtype of BCC made up of little round collections of cancer cells, called "Nodular". There is almost no data on the use of vismodegib in other subtypes of BCC that that tend to extend deep into the skin ("Infiltrative" subtype), or spread widely near the surface of the skin ("Superficial" subtype).

A total of 36 subjects will be enrolled in the study. All study participants will receive oral vismodegib treatment.

At the Week 12 visit, skin biopsies will be performed to give the investigators more information on how the tumor is responding to vismodegib. If there is no evidence of tumor on the biopsy, the subject will be eligible to end treatment early and enter the Observation period. During this time the subject will be followed clinically every 3 months for up to 1 year.

For all other subjects, if any evidence of tumor is seen on biopsy at week 12, the subject will continue treatment for the full 24 weeks. At week 24 visit, skin biopsies will be performed again to see if there is any tumor left. If there is no evidence of tumor on the biopsy, the subject will be eligible to end treatment early and enter the Observation period. If there is tumor left, the subject will be referred for surgery or other standard of care treatment to remove the tumor.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ML28485:Phase 2B Single-site,Open-label,Nonrandomized Study Evaluating Efficacy of Oral Vismodegib in Various Histologic Subtypes (Infiltrative/Morpheaform,Nodular and Superficial)of High Risk and/or Locally Advanced Basal Cell Carcinoma
Actual Study Start Date : January 14, 2013
Actual Primary Completion Date : July 3, 2017
Actual Study Completion Date : July 3, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Vismodegib

Arm Intervention/treatment
Experimental: Open Label oral vismodegib
This is a Phase 2B single-site, open-label, nonrandomized 24-week study of the efficacy and safety of vismodegib (150 mg PO daily) in subjects with high risk and/or locally advanced basal cell carcinoma (BCC). A total of 36 subjects with infiltrative/morpheaform, nodular, or superficial BCC will be enrolled in the study.
Drug: vismodegib (150 mg PO daily)
Biopsies will be performed on all participants at baseline, week 12 and week 24.
Other Name: Brand name: Erivedge




Primary Outcome Measures :
  1. Efficacy of Vismodegib [ Time Frame: Week 24 ]
    The efficacy of vismodegib was defined as the number of tumor biopsies with positive pathology after 24 weeks. Subjects had one target lesion and up to 3 additional non-target lesions. A cumulative total of 65 tumors was measured after 24 weeks of treatment. Histopathological subtypes were categorized primarily as infiltrative, nodular and superficial.


Secondary Outcome Measures :
  1. Safety of Vismodegib [ Time Frame: Up to 18 months ]
    The safety of Vismodegib was evaluated by monitoring adverse effects. All adverse events, expected and unexpected, were recorded and categorized using the Common Terminology Criteria for Adverse Events (CTCAE) guide. This is a set of criteria from the National Cancer Institute (NCI) used to standardize classification of adverse effects of drugs. Grade 1 events are defined as mild, grade 2 as moderate, grade 3 as severe; grade 4 as life-threatening and grade 5 as death.

  2. Onset of Efficacy of Vismodegib [ Time Frame: Up to week 24 ]
    Onset of efficacy was measured by tumor surface area reduction or increase. Subjects had one target lesion and up to 3 additional non-target lesions. Surface area of a cumulative total of 65 tumors (27 target lesions and 38 non-target lesions) was measured after 24 weeks of treatment. A complete response was defined as 100% reduction in tumor surface area. Partial response was defined as greater than 50% reduction in tumor surface area. Stable disease was defined as less than 50% reduction in tumor surface area and Progressive disease was defined as greater than 20% increase in tumor surface area.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. A signed and data informed consent
  2. Willing to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
  3. 18 years of age or older at time of informed consent
  4. Have one or more clinically suspicious lesions for BCC at Pre-Study screening Visit that has:

    1. a diameter ≥ 6 mm if located on the "mask areas" of face (central face, eyelids, eyebrows, periorbital,nose,lips,chin,mandible,preauricular and postauricular skin/sulci,temple,ear),genitalia,hands,or feet
    2. a diameter ≥ 10 mm if located on cheeks,forehead,scalp,or neck
    3. a diameter ≥ 20 mm if located on trunk and extremities

      or has a lesion suspicious for locally advanced BCC defined as a lesion that:

    4. is ≥ 10 mm,
    5. has recurred following surgery or surgical resection would result in substantial deformity, and
    6. has been deemed not appropriate for radiation.
  5. Have a histologically-confirmed BCC prior to first dose of study drug
  6. Have an Eastern Cooperative Oncology Group performance status of 2 or less at Baseline
  7. Female of reproductive potential must use 2 effective methods to avoid pregnancy during therapy and for 7 months after completing therapy
  8. Male patients must use effective measures to avoid pregnancy in their partner at all times during treatment and for 2 months after the last dose
  9. Agree not to donate blood or blood products during the study and for 7 months after the last dose
  10. Subjects with Basal Cell Nevus Syndrome are eligible for enrollment

Exclusion Criteria:

  1. Women who are pregnant, lactating, or planning pregnancy while in the study
  2. History of prior treatment with vismodegib or any Hh Pathway Inhibitor
  3. Evidence of clinically significant and unstable diseases or conditions; Subjects with clinically stable chronic medical conditions will be allowed to enter the study
  4. Any dermatological disease at treatment site that the investigator thinks may be exacerbated by treatment with vismodegib or cause difficulty with examination
  5. The target lesion identified at Pre-study Screening visit has been determined to be mBCC by radiological assessment prior to first dose of study drug
  6. Inability or unwillingness to swallow capsules
  7. History of infection requiring hospitalization, IV antimicrobial therapy, or is otherwise judged to be clinically significant by the investigator within 4 wks prior to first dose of study drug
  8. History of infection requiring antimicrobial therapy within 2 wks prior to first dose of study drug
  9. History of alcohol or substance abuse, unless in full remission for greater than 6 months prior to first dose of study drug
  10. Known to be infected with human immunodeficiency virus, hepatitis B or hepatitis C viruses
  11. Participation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before the study begins and/or during study participation
  12. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results in the judgment of the investigator
  13. Subjects who are study site staff members or who are Sponsor employees directly involved in the conduct of the trial
  14. A subject who, in the opinion of the investigator or sponsor, will be uncooperative or unable to comply with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01700049


Locations
Layout table for location information
United States, Missouri
Saint Louis University Department of Dermatology
Saint Louis, Missouri, United States, 63104
Sponsors and Collaborators
Mayo Clinic
Genentech, Inc.
Investigators
Layout table for investigator information
Study Director: Scott Fosko, MD fosko.scott@mayo.edu
  Study Documents (Full-Text)

Documents provided by Scott W. Fosko, Mayo Clinic:

Additional Information:
Publications:

Layout table for additonal information
Responsible Party: Scott W. Fosko, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01700049     History of Changes
Other Study ID Numbers: ML28485
22355 ( Other Identifier: Saint Louis University )
First Posted: October 4, 2012    Key Record Dates
Results First Posted: May 23, 2019
Last Update Posted: May 23, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Scott W. Fosko, Mayo Clinic:
advanced BCC
high risk
locally advanced

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Basal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Basal Cell